Tag: Policy

This month has been marked by progress in both the regulatory and investment sides of rejuvenation biotechnology. For years, the field has faced two major challenges: scientific advances outpacing the regulatory systems meant to evaluate them, and a capital environment that has often struggled to distinguish serious translational work from noise and hype. Fortunately, recent...

Researchers are developing biomedical repair therapies to address multiple age-related diseases at once, yet they are forced to put them through regulatory pathways built for single-disease drugs. The result is delay, duplication, and unnecessary cost precisely when speed matters the most. The single-disease-indication trap Current regulation still treats age-related diseases as if they were a...

At a panel in Boston, senior officials announced plans to include aging in the agency’s regulatory science agenda and discussed how therapies could move toward approval. Longevity has a partner The 2026 edition of the Aging Research and Drug Discovery Meeting (ARDD) kicked off yesterday. This is one of the biggest and longest-running longevity conferences,...

Worldwide healthcare faces an unsustainable situation. We spend trillions managing the late-stage effects of biological aging, yet routinely overlook the underlying causes that drive them. Driven by an aging society, the financial burdens of treating diabetes, dementia, and heart disease are pushing Social Security and Medicare towards increasing and potentially catastrophic budget deficits [1]. Treating...

Montana’s first experimental treatment review board has brought three longevity heavyweights into the state’s effort to expand access to experimental therapies. How much regulation is too much? Many people in the longevity field will tell you that regulation is holding it back. Sensible oversight of novel therapies is essential, but an overly cautious interpretation of...

In this follow-up interview, we speak with Gabriel Cian about how the 2060 ecosystem has evolved since last year’s Forum, what he learned from the first edition, and how he is thinking about investment, scientific credibility, health optimization, policy, and the future of longevity in Europe. Last year, we spoke about your path from software...